Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published 15 May 2007 Volume 2007:3(2) Pages 237—243

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

Electrospun fibrous scaffolds combined with nanoscale hydroxyapatite induce osteogenic differentiation of human periodontal ligament cells

Wu XN, Miao LY, Yao YF, Wu WL, Liu Y, Chen XF, Sun WB

International Journal of Nanomedicine 2014, 9:4135-4143

Published Date: 27 August 2014

Synthesis, characterization, and evaluation of paclitaxel loaded in six-arm star-shaped poly(lactic-co-glycolic acid)

Chen Y, Yang Z, Liu C, Wang C, Zhao S, Yang J, Sun H, Zhang Z, Kong D, Song C

International Journal of Nanomedicine 2013, 8:4315-4326

Published Date: 7 November 2013

Fabrication and in vitro release behavior of a novel antibacterial coating containing halogenated furanone-loaded poly(L-lactic acid) nanoparticles on microarc-oxidized titanium

Cheng YC, Wu J, Gao B, Zhao XH, Yao JY, Mei SL, Zhang L, Ren HF

International Journal of Nanomedicine 2012, 7:5641-5652

Published Date: 7 November 2012

Nanotechnology-based approaches in anticancer research

Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA

International Journal of Nanomedicine 2012, 7:4391-4408

Published Date: 9 August 2012

Chronic airflow limitation in a rural Indian population: etiology and relationship to body mass index

Chakrabarti B, Purkait S, Gun P, Moore VC, Choudhuri S, Zaman MJ, Warburton CJ, Calverley PMA, Mukherjee R

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:543-549

Published Date: 18 October 2011

Inflammatory mediators: Parallels between cancer biology and stem cell therapy

A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar

Journal of Inflammation Research 2009, 2:13-19

Published Date: 4 February 2009

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis

Richard A Hansen, Gerald Gartlehner, Aaron P Webb, Laura C Morgan, Charity G Moore, Daniel E Jonas

Clinical Interventions in Aging 2008, 3:211-225

Published Date: 6 June 2008

Studies on free radicals, antioxidants, and co-factors

Khalid Rahman

Clinical Interventions in Aging 2007, 2:219-236

Published Date: 15 July 2007